|
1
|
Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy 2019; 11:1337-1351. [DOI: 10.2217/imt-2019-0125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
ABP 215 (MVASI™) is the first approved biosimilar to Avastin® (bevacizumab). It is approved in the USA and the European Union (EU) for all bevacizumab indications in these jurisdictions except for ovarian cancer in the USA due to orphan drug exclusivity. ABP 215 was shown to be structurally, functionally and clinically (pharmacokinetic, efficacy and safety) similar to the bevacizumab reference product; the pharmacokinetic study was conducted in healthy adult men (n = 202); safety and efficacy were evaluated in patients with advanced nonsquamous non-small-cell lung cancer (n = 642). Together, these results comprise the totality of evidence that provides scientific justification for extrapolation to all approved indications of the reference product and supports the clinical value of ABP 215 as an additional treatment option.
Collapse
Affiliation(s)
- Michael Thomas
- Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center, Heidelberg, Germany
| | - Nick Thatcher
- Department of Medical Oncology, School of Cancer and Imaging Sciences, University of Manchester, Christie Hospital, Manchester, UK
| | - Jerome Goldschmidt
- Oncology & Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, VA 24060, USA
| | - Yuichiro Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji Chou-ku, Tokyo 104-0045, Japan
| | - Helen J McBride
- Biosimilars Business Unit, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| | - Vladimir Hanes
- Biosimilars Business Unit, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| |
Collapse
|